Resolution Therapeutics Builds Momentum Around RTX001 as Preclinical Data and Conference Visibility Grow

Resolution Therapeutics, a private biotech focused on macrophage-based cell therapies, spent the week building scientific and clinical momentum around RTX001, its lead regenerative macrophage therapy for end-stage liver disease. The company positioned recent and upcoming data disclosures as foundational to the Phase I/II EMERALD trial now underway in the U.K. and Spain.

Multiple LinkedIn updates highlighted that RTX001 preclinical data will be presented by senior scientist Lara Campana at the ASGCT Annual Meeting in Boston in 2026. The dataset spans pharmacology, safety, tolerability and efficacy in several mouse models, with treatment associated with reduced liver enzymes, inflammation and fibrosis, and a favorable safety profile.

Resolution said the findings support RTX001’s potential dual local and systemic anti-inflammatory activity, a key consideration for patients experiencing systemic inflammatory spikes during liver decompensation events. The company is positioning RTX001 as a potential first-in-class regenerative, immunomodulatory therapy for end-stage liver disease, although interim EMERALD data are not expected until the second half of 2026.

Management also framed RTX001 within a broader cell and gene therapy shift observed at the ISCT 2026 meeting in Dublin, where attention is moving beyond CAR-T and rare disease gene therapy toward regenerative indications such as liver disease and Type I diabetes. Conference feedback emphasized rising interest in macrophages, mesenchymal stem cells and extracellular vesicles, as well as growing collaboration among sponsors, regulators and payers.

Resolution reported increased engagement with hepatology and gastroenterology experts through planned participation at Digestive Disease Week and other industry events, aiming to elevate RTX001’s profile and potential partnering visibility. The company is also exploring its macrophage engineering platform in additional inflammatory and fibrotic indications, including graft-versus-host disease and lung fibrosis.

Operationally, Resolution strengthened its organization by appointing Louise Rowe as vice president of operations and highlighting advances in AI- and automation-enabled manufacturing and supply chain capabilities. The firm underscored proactive regulatory planning, with executives participating in panels on evolving FDA and EMA expectations and emphasizing CDMO oversight and early alignment with guidance.

The company’s leadership noted growing interest in artificial intelligence for discovery and development, while acknowledging that major efficiency gains in GMP manufacturing may take longer to materialize. Overall, this week’s news suggests Resolution Therapeutics is consolidating its scientific credibility, operational readiness and regulatory strategy as it prepares for pivotal RTX001 readouts in the coming years.